Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Releases Quarterly Earnings Results

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.10), Zacks reports.

Lakewood-Amedex Biotherapeutics Stock Down 22.3%

LABT traded down $0.06 during midday trading on Monday, hitting $0.22. 828,332 shares of the company were exchanged, compared to its average volume of 7,485,027. The business has a 50 day moving average of $0.99. The stock has a market cap of $519,978.00 and a price-to-earnings ratio of -0.05. Lakewood-Amedex Biotherapeutics has a 1-year low of $0.17 and a 1-year high of $98.20.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on LABT shares. HC Wainwright started coverage on shares of Lakewood-Amedex Biotherapeutics in a research report on Wednesday, October 28th. They issued a “buy” rating on the stock. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. Finally, Wall Street Zen lowered Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Lakewood-Amedex Biotherapeutics presently has an average rating of “Hold”.

View Our Latest Research Report on Lakewood-Amedex Biotherapeutics

About Lakewood-Amedex Biotherapeutics

(Get Free Report)

Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.

Featured Articles

Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.